Cellworks Research India, the Bangalore-based research and development (R&D) wing of Cellworks Group Inc (California-headquartered company), has assisted Chennai-based Orchid Chemicals and Pharmaceuticals by providing system biology technology in carrying out ongoing New Chemical Entity (NCE) research programme.
PhysioStim of France, a specialist in cardiac safety pharmacology, is setting up a new model for isolated cardiomyocytes, which will record all types of ionic currents and action potentials.
Private equity (PE) major ICICI Ventures is acquiring Chennai-based standalone pharmaceutical and
veterinary company Alved Pharma and Foods. RFCL, a wholly-owned veterinary, chemicals and medical
diagnostic company of ICICI Ventures, is learnt to have signed a definitive agreement with Alved Pharma and Foods for a complete buyout.
A pharma packaging company Bilcare Research of Pune has launched a product to help check the menace of counterfeit drugs. The product has a label with a unique bar code made out of nanotechnology and fingerprinting.
US-based $23-billion diversified technology firm 3M is in talks with top domestic pharma companies to licence drug delivery technologies.
In a major blow to chemists charging hefty margins from consumers, the government has decided to limit trade margins on all medicines sold in the country.
ICICI Venture is planning to float a company that will buy medium-sized hospitals and pharmacy chains and act as a holding company for the fund
Pfizer, a US-based pharmaceutical giant, is looking to cut costs by outsourcing as much as 30 per cent of its manufacturing to facilities in Asia, particularly in India and China.
The pharma sector may have underperformed in the Sensex , but companies providing contract research and manufacturing services (CRAMS) to global pharma companies have given good returns.
IBM is targeting multi-billion dollar health business opportunities in India. The company has plans to tap opportunities worth $1 billion each in the Indian pharmaceuticals and health service segments over the next 3-4 years.
US-based private equity fund Citi Venture Capital (CVC) has picked up nearly 30% stake in Mumbai-based bulk drug maker Unimark Remedies for INR 113 crore. The transaction, one of the largest investments in the pharma sector in 2007 and CVC
Ranbaxy Laboratories may dilute up to 60% stake in its new research company, which will be formed by hiving off its R&D unit into a separate entity in 2008.
Nicholas Piramal (NPIL) has reportedly signed a research deal potentially worth a maximum revenue of USD 350 million with US pharmaceutical giant Merck & Co to carry out early discovery and development of two new cancer drugs, the two companies said on Monday.
